Pleural mesothelioma is an aggressive cancer caused by asbestos exposure. It forms in the lining of the lungs. The prognosis is poor for most patients, but early diagnosis and effective treatment can improve life expectancy.
Pleural mesothelioma is a malignant cancer that develops in the pleura, the two layers of tissue that surround and protect the lungs.
It is the most common type of mesothelioma, accounting for approximately 75 percent of cases.
The disease is caused by exposure to asbestos. People who worked with asbestos products are most at risk.
A long latency period of 20 to 50 years transpires between exposure and development of the cancer. It takes decades for asbestos to cause the genetic damage that leads to pleural mesothelioma.
Once the cancer develops, it progresses quickly. Unfortunately, the first symptoms of the cancer arise after tumors have progressed into a late stage of development. This is the primary reason the disease is often diagnosed too late for surgery to work.
While surgery is considered the best treatment to improve prognosis, it isn’t the only option. Other treatments can extend life expectancy including chemotherapy, radiation therapy, immunotherapy, gene therapy and photodynamic therapy.
Clinical trials are testing and refining these therapies, and researchers are working hard to find better ways of controlling the disease. While there is no cure for pleural mesothelioma, many patients can live a long time with the cancer thanks to advances in treatment technologies.
Pleural mesothelioma is primarily caused by exposure to asbestos, a mineral that was once widely used in many commercial and domestic products.
It generally takes years of repeated exposure to asbestos to become at risk of developing pleural mesothelioma. The people who develop the cancer usually worked with asbestos products throughout their career.
Sometimes the family members of asbestos workers end up developing pleural mesothelioma. Known as secondary exposure, this kind of exposure happens when workers unknowingly bring asbestos fibers home on their work clothes.
As the cancer progresses, more serious symptoms may develop such as difficulty swallowing, back pain and nerve pain.
Many patients may experience symptoms associated with pleural effusion, which is a buildup of fluid around the lungs. This condition may cause shortness of breath and a feeling of pressure inside the chest.
Primary care doctors often order a chest X-ray when patients present symptoms. Difficulty breathing and chest pain are the most common symptoms that bring patients to the doctor.
An X-ray may reveal something suspicious on or around the lungs, prompting the doctor to refer a patient to a pulmonologist, oncologist or local hospital for additional testing.
Tissue biopsies and advanced imaging scans are required to make an official pleural mesothelioma diagnosis. Tissue biopsies help doctors confirm the precise type of cancer present. Imaging scans — such as CT and PET scans — help stage how far along the cancer has progressed.
The most widely used method of staging is the Tumor, Node, Metastasis (TNM) system. The International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) have adopted this system.
Pleural mesothelioma cancer growth is categorized into four stages. As the stage number increases, prognosis becomes poorer and survival rates decrease.
A patient’s stage at diagnosis is the most important factor for determining treatment options.
Pleural mesothelioma is treated with chemotherapy, surgery, radiation therapy and certain experimental therapies.
The most commonly administered chemotherapy drugs for pleural mesothelioma are carboplatin/cisplatin and pemetrexed. Recent studies have shown that the addition of a third drug, bevacizumab, improves survival in mesothelioma patients.
Approximately 80 percent of patients are diagnosed too late to qualify for surgery.
Radiation therapy is sometimes used following surgery to improve local control of tumor. However, studies do not show the addition of radiation therapy results in longer survival.
Experimental therapies, including immunotherapy, gene therapy and photodynamic therapy, are available through clinical trials. Patients may be able to access immunotherapy drugs through compassionate use programs.
Many patients use complementary therapies in addition to these conventional cancer treatments. Known as integrative oncology, this approach uses safe complementary therapies to help ease the side effects of cancer treatment. Examples of complementary therapies include acupuncture, yoga and meditation.
Lebenthal trained under mesothelioma treatment pioneer Dr. David Sugarbaker and has dedicated part of his career to helping veterans with mesothelioma. He splits his time operating at the VA Boston Healthcare System and Brigham and Women’s Hospital. He also teaches up-and-coming surgeons at Harvard Medical School.
Flores is the chief of thoracic surgery and director of the Thoracic Surgical Oncology program at Mount Sinai Medical Center in New York. He is renowned for his surgical expertise and bedside manner. He helped pioneer the use of intraoperative chemotherapy for pleural mesothelioma. Flores is known for his low surgical complication rates and his friendly manner with patients.
Cameron is the pioneer of a surgical procedure for pleural mesothelioma known as the pleurectomy and decortication, which keeps both lungs intact. As the director of UCLA’s Comprehensive Mesothelioma Program, Cameron’s patients enjoy a higher quality of life post-surgery thanks to the preservation of both lungs. Cameron is involved in pleural mesothelioma research and improving surgical approaches for the cancer.
The prognosis for most pleural mesothelioma patients is poor. The disease shortens life expectancy by an average of 10.6 years, according to a 2013 study published in the American Journal of Industrial Medicine.
The overall survival is 9 to 17 months after diagnosis.
A 2015 study published in Translational Oncology reported the following survival rates for pleural mesothelioma:
Improving prognosis involves working with a mesothelioma expert to get the best possible treatment.
Joining a clinical trial is a common option for patients who don’t respond well to first-line treatment. Innovative therapies — such as immunotherapy and gene therapy — are available through clinical trials.
Even though there is no cure for pleural mesothelioma, patients may improve their prognosis by working with an expert doctor and participating in clinical trials.